Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes.
Type 1A diabetes (T1D) is caused by autoimmune islet beta cell destruction precipitated by environmental triggers in genetically predisposed individuals. Islet beta cells produce insulin and are the primary target of this autoimmune disorder. Insulin, glutamic acid decarboxylase, and insulinoma associated-2 autoantibodies (IAA, GAD65, and IA-2) are the autoantibodies that have been associated most clearly with the development of T1D. Despite our current ability to predict T1D using genetic markers and detecting islet autoantibodies, we have yet to find a safe way to prevent the disease. However, there are more than 100 different therapies that prevent T1D in the nonobese diabetic (NOD) mouse model or the BioBreeding (BB) rats. This paper reviews a few select therapeutic approaches that have been or are being evaluated as possibilities for the prevention, amelioration, or cure of T1D.
Aly
Theresa
T
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO, USA.
Devendra
Devasenan
D
Eisenbarth
George S
GS
D000818:Animals; D001323:Autoantibodies / Q000302:isolation & purification; D016572:Cyclosporine / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009536:Niacinamide / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D051381:Rats
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D009536:Niacinamide; D016572:Cyclosporine